



FDA-20207MNAIMYE4XQY4AK2B7GM



Republic of the Philippines  
Department of Health  
**FOOD AND DRUG ADMINISTRATION**  
Civic Drive, Filinvest Corporate City, Alabang, Muntinlupa City



## CERTIFICATE OF PRODUCT REGISTRATION

Pursuant to the provisions of Republic Act (R.A.) No. 3720 as amended, known as the Foods, Drugs, Devices and Cosmetics Act, and consistent with R.A. No. 6675, known as the Generics Act of 1988, and R.A. No. 9711, otherwise known as the Food and Drug Administration Act of 2009, the product described hereunder has been found to conform with the requirements and standards for marketing authorization of pharmaceutical products per existing regulations in force as of date hereof.

**Registration Number** : DR-XY46910

**Generic Name** : Ascorbic Acid  
**Brand Name** : UNO Ultima-C  
**Dosage Strength & Form** : 500mg (equivalent to 562.43mg Sodium Ascorbate) Capsule  
**Pharmacologic Category** : Vitamin  
**Classification** : Over-the-Counter (OTC) Drug  
**Approved Shelf-life** : 24 months  
**Storage Condition** : Store at temperatures not exceeding 30°C. Protect from heat, light and moisture.  
**Packaging** : Alu/PVC Blister Pack x 10's (Box of 100's)

**Manufacturer** : Compact Pharmaceuticals Corp.  
17 Sta. Monica St., Malinta, Valenzuela, Metro Manila

**Distributor** : Unlimited Network of Opportunities International Corporation  
108 Octo Arts Building 2, Panay Avenue, Quezon City, Metro Manila

The marketing authorization shall be valid until **15 June 2025** subject to the conditions listed on the reverse side. No change in the formulation, labelling and commercial presentation of this product shall be made at any time during the effectivity of this registration without prior written approval of this Office.

This marketing authorization is subject to suspension, cancellation or recall should any violation of R.A. No. 3720, R.A. No. 6675 and R.A. No. 9711 and/or regulations issued thereunder involving the product be committed.

Witness My Hand and Seal of this Office, this **15 June 2020**.

By Authority of the Director General  
Per FDA Order No. 2016-005

**JESUSA JOYCE N. CIRUNAY, RPh**  
Director IV  
Center for Drug Regulation and Research

REG. STATUS : Initial  
AMOUNT : Php 15,150.00; Php 510.00  
OR NUMBER : 1240053; 1261300  
DATE : 28 January 2020; 01 April 2020

BAR CODE :  
DOC TRACK :



2 0 1 9 1 2 0 3 0 9 0 5 4 1



Management System  
ISO 9001:2015



FDA-0448792



Republic of the Philippines  
Department of Health  
**FOOD AND DRUG ADMINISTRATION**



**CERTIFICATION**

This is to certify that the product with the following particulars:

Product Name	Registration Number	CPR Validity
Ascorbic Acid (as Sodium Ascorbate) 500 mg Capsule [UNO Ultima-C]	DR-XY46910	15 June 2025

has been given approval for the following post-approval change/s:

Previous	Proposed Change	Classification
Brand name: UNO Ultima-C	Proposed: <b>Ultima-C</b>	Change from unbranded to branded drug [MiV-PH02]

The Marketing Authorization Holder, **Unlimited Network of Opportunities International Corporation**, with business address at 108 Octo Arts Building 2, Panay Avenue, Quezon City, shall attach this certification or copy of the certification to the Certificate of Product Registration.

Issued this 3<sup>rd</sup> day of March 2022 at Alabang, Muntinlupa City, Philippines.

**By Authority of the Director General  
Per FDA Order No. 2016-005**

**JESUSA JOYCE N. CIRUNAY, RPh**  
Director IV, Center for Drug Regulation and Research

REG. STATUS : Initial (Variation)  
OTHER DTN : 20211214121038  
AMOUNT : Php 3,030.00  
O.R NUMBER : Seq. #: 112520206513  
DATE : 25 Nov. 2020



Conditions:

- [x] A maximum of twelve (12) months after the issuance of this Certification is hereby given to exhaust all existing inventory of the previous labeling materials (primary, secondary, and product information). No further extension will be granted.
- [x] Subject to post-marketing surveillance of the marketing authorization holder's strict compliance to the Generic Labeling Requirements following the applicable provisions of A.O. No. 2016-0008 for drug products for human use and A.O. 105 s. 1991 for veterinary drug products.
- [ ] Subject to post-marketing surveillance of the marketing authorization holder's strict compliance to the Generic Labeling Requirements following the applicable provisions of A.O. No. 2016-0008 upon renewal registration.